Abacavir/Lamivudine/Zidovudine Continues to be a Valid and Useful Antiretroviral Regimen

Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Salten GA Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.

Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. March 23, 2004. http://aidsinfo.nih.gov (accessed 2004 May 21).

Chow YK Hirsch MS Merrill DP Bechtel LJ Eron JJ Kaplan JC Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993;361:650–4.

Gulick RM Ribaudo HF Shikuma CM Lustgarten S Squires KE Meyer WA Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850–61.

Staszewski S Keiser P Montaner J Raffi F Gathe J Brotas V Abacavir—lamivudine—zidovudine vs indinavir—lamivudine—zidovudine in antiretroviral-naïve HIV-infected adults: A randomized equivalence trial. JAMA 2001;285:1155–63.

Vibhagool A , on behalf of the CNA3014 International Study Team. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir (IDV/COM) in HIV-1-infected antiretroviral therapy naïve adults: results of a 48-week open-label study (CNA3014) (abstract 063). In: Programs and Abstracts from the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8–11, 2001.

Matheron S Descamps D Boué F Livrozet JM Lafeuillade A Aquilina C Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: A randomized trial. Antivir Ther 2003;8:163–71.

Kumar P Rodriguez-French A Thompson M Tashima K Wannamaker P Williams V Prospective study of hyperlipidemia in ART-naïve subjects taking Trizivir (TZV), Combivir (COM)/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (abstract 709). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Lafeuillade A Clumeck N Mallolas J Jaeger H Livrozet JM Ferreira Mdo S Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: The Trizal Study. HIV Clin Trials 2003;4:37–43.

Martínez E Anaiz JA Podzamczer D Dalmau D Ribera E Momingo P Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency infection. N Engl J Med 2003;349:1036–46.

Farthing C Khanlou H Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in treatment-naïve HIV-infected patients (oral presentation). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Gallant JE Rodriguez A Weinberg W Young B Berger D Lim ML Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis (oral presentation H-1722a). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003.

US Food and Drug Administration. Important drug warning: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir. www.fda.gov/oashi/aids/new.html (accessed 2003 Oct 14).

Johnson VA Brun-Vezinet F Clotet B Conway B D'Aquila RT Demeter LM International AIDS Society—USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med 2003;11:215–21.

Cote HCF Brumme ZL Craib KJ Alexander CS Wynhoven B Ting L Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811–20.

McComsey GA Ward DJ Hessenthaler SM Sension MG Shalit P Lonergan JT Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus—infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004;38:263–70.